Who Owns Artivion Company?

Artivion Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Artivion?

Uncover the financial backbone of a leading medical device innovator. Exploring the Artivion SWOT Analysis is just the beginning; understanding its ownership structure reveals the forces shaping its future. From its inception as CryoLife to its current status, Artivion's journey is a testament to strategic evolution.

Knowing who owns Artivion, the Artivion company, is crucial for investors and stakeholders alike. This analysis will dissect the Artivion ownership landscape, from major shareholders to the influence of public investors and the leadership team. The insights gleaned will provide a comprehensive understanding of Artivion's strategic direction and market position. This includes insights into Artivion stock and its potential for growth.

The company now known as Artivion, Inc., began its journey in 1984 as CryoLife. The founders of the company were Steven Anderson and Robert McNally. The company's initial focus was on cryopreservation of human heart valves and tissues for transplant purposes.

Steven Anderson served as the president and CEO from the company's inception. The original headquarters was in Sarasota, Florida. Later the company moved its headquarters to Kennesaw, Georgia.

Information about the initial equity splits or detailed shareholding percentages for the founders is not publicly available. Details regarding early backers, angel investors, or specific friends and family who acquired stakes during the initial phase are also not readily available in public records.

Founding of Artivion

Artivion, formerly CryoLife, was established in 1984. It was founded by Steven Anderson and Robert McNally.

Initial Focus

The company's early work centered on the cryopreservation of human heart valves and tissues. This was for use in transplants.

Leadership

Steven Anderson was the president and CEO from the company's beginning. He was key to the early direction of the company.

Headquarters

Initially based in Sarasota, Florida, the company later moved its headquarters. The new location was Kennesaw, Georgia.

Ownership Details

Specific information about initial equity splits is not available. Details of early investors are also not publicly accessible.

Early Agreements

Information on early agreements, such as vesting schedules, is not readily available. This information is not typically released to the public.

The early history of the company provides context for understanding the current Artivion owner structure and the evolution of Artivion ownership. For a deeper dive into the company's origins, you can read more in the Brief History of Artivion. While it's challenging to pinpoint the exact initial ownership details, the company's focus on medical advancements has remained a constant. Understanding who owns Artivion involves examining its history and current shareholder structure.

Key Points on Founders and Early Ownership

The founders, Steven Anderson and Robert McNally, established the company in 1984.

• The initial focus was on cryopreservation of human heart valves and tissues.
• Steven Anderson served as president and CEO from the start.
• Specific details on early equity splits or early investors aren't available in public records.
• The company's headquarters moved from Florida to Georgia.

Artivion SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Artivion, Inc. (formerly CryoLife, Inc.) transitioned to a publicly traded entity on February 11, 1993, following an Initial Public Offering (IPO). This strategic move facilitated access to capital, crucial for fueling expansion and advancements in research and development. The company's shares are traded on the New York Stock Exchange (NYSE) under the ticker symbol AORT. The evolution of Artivion's ownership structure reflects its growth and adaptation within the medical device industry, with key acquisitions and strategic decisions shaping its market position and investor appeal.

The ownership of Artivion is largely dominated by institutional investors, a common characteristic among established public companies in the medical device sector. As of May 2025, these institutional investors collectively hold approximately 95.40% of the company's stock. Insiders own 6.79%, and mutual funds account for 69.25% of the shares. According to data from June 9, 2025, there are 438 institutional owners and shareholders, who collectively possess 52,281,655 shares.

Major institutional shareholders include BlackRock, Inc., Macquarie Group Ltd, Fmr Llc, Perceptive Advisors Llc, Vanguard Group Inc, iShares Core S&P Small-Cap ETF (IJR), Morgan Stanley, Delaware Small Cap Core Fund Class A (DCCAX), Juniper Investment Company, LLC, and Wellington Management Group Llp. iShares is noted as owning the most shares of Artivion. Significant acquisitions, such as On-X Life Technologies Holdings, Inc. in 2016 and Ascyrus Medical GmbH in 2020, have influenced Artivion's strategic direction and, by extension, its valuation and attractiveness to investors. For more insights, you can explore the Marketing Strategy of Artivion.

Key Takeaways on Artivion Ownership

Institutional investors hold the majority of Artivion's stock, reflecting its status as a publicly traded company. Key acquisitions have played a role in shaping the company's strategic direction and investor appeal.

• Institutional ownership is approximately 95.40% as of May 2025.
• The company's market capitalization was approximately $1.35 billion as of June 12, 2025.
• Strategic acquisitions have expanded the company's product portfolio and market presence.

Artivion PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors of Artivion, Inc. oversees the company's strategic direction and represents shareholder interests. As of May 2025, the stockholders approved the election of nominated individuals to the board. Information about the board members and their roles is detailed in the company's definitive proxy statements, which are publicly available. Understanding who owns Artivion is crucial for investors.

James Mackin serves as the Chairman of the Board, President, and CEO. Other board members include Jeff Burbank (Lead Director), Elizabeth A. Hoff, Jon W. Salveson, and Thomas F. Ackerman. The proxy statement from April 1, 2025, indicates that ownership representing less than 1% of the outstanding shares of common stock is held by certain individuals on the board. For those interested in the Target Market of Artivion, understanding the company's leadership is essential.

Artivion operates with a standard voting structure where shareholders of record can vote directly, and beneficial owners can vote through a 'legal proxy'. The voting structure generally follows a one-share-one-vote principle for common stock. Proposals such as additional funding require a majority of shares present and entitled to vote. Abstentions count as 'Against' votes, while broker non-votes do not affect the outcome. There are no known individuals or entities with special voting rights beyond the standard common stock voting rights. Information about Artivion ownership is transparent through public filings.

Voting Power and Shareholder Rights

Shareholders vote based on a one-share-one-vote principle, and beneficial owners vote via legal proxy. Understanding shareholder rights is key for those who invest in Artivion stock.

• One Share, One Vote: Common stock voting rights.
• Proxy Voting: Beneficial owners vote through their brokers.
• Majority Rules: Proposals require a majority of shares present.
• No Special Rights: No known entities with outsized voting control.

Artivion Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

In recent years, the ownership structure of Artivion has been shaped significantly by its status as a publicly traded company and its financial activities. As of May 2025, institutional investors hold a substantial portion, approximately 95.40%, of Artivion's stock. Insiders own 6.79%, and mutual funds account for 69.25% of the shares. This concentration of ownership among institutional investors highlights the confidence these entities place in the company's long-term prospects. The Growth Strategy of Artivion has played a crucial role in shaping the ownership profile.

Significant financial transactions have also influenced the ownership landscape. In May 2025, Artivion completed exchanges of its 4.250% Convertible Senior Notes due 2025 for common stock, totaling $99.5 million. This type of exchange can alter the number of outstanding shares, subsequently affecting ownership percentages. Furthermore, in 2024, the company raised $5.7 million through the exercise of stock options and the issuance of common stock. These financial maneuvers are indicative of the company's efforts to manage its capital structure and fund its growth initiatives.

The evolution of Artivion's ownership reflects broader industry trends. The increasing presence of institutional investors and the typical dilution of founder ownership as a company matures and becomes public are evident. While founders Steven Anderson and Robert McNally established the company, their direct ownership has become less prominent compared to institutional holdings. With anticipated revenue growth of 11% to 14% in 2025, and ongoing strategic initiatives like the anticipated commercialization of BioGlue in China and the pursuit of PMA approval for the AMDS hybrid prosthesis in the US, the company's future ownership trends and investor interest will continue to evolve.

Artivion Stock Performance

The share price of Artivion (AORT) increased by 25.44% between June 10, 2024, and June 9, 2025, reaching $29.19 per share.

Key Financial Activities

In May 2025, Artivion exchanged $99.5 million in convertible notes for common stock. In 2024, the company raised $5.7 million from stock options.

Future Outlook

Artivion anticipates commercializing BioGlue in China by the second half of 2025 and is seeking PMA approval for the AMDS hybrid prosthesis in the US by 2026.

Revenue Growth

The company expects revenue growth of 11% to 14% in 2025, which is likely to influence future ownership trends.

Artivion Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs